Lipid Nanoparticles in Drug Delivery: Advances, Challenges, and Clinical Prospects

Lipid nanoparticles have emerged as a highly promising platform for drug delivery, offering remarkable advantages such as biocompatibility, ease of preparation, scalability, and the ability to encapsulate a wide range of therapeutic agents including hydrophilic and hydrophobic drugs as well as nucleic acids. Over the past decades, significant progress has been made in the design and optimization of various types of LNPs, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, each tailored to balance stability, drug loading, and release profiles. Advances in lipid chemistry, helper lipids, and surface modification strategies have enhanced delivery efficiency and reduced toxicity, enabling clinical successes such as FDA-approved mRNA vaccines and RNAi therapies. Despite these advances, challenges remain in achieving long-term stability, overcoming biological barriers such as the blood-brain barrier, managing immunogenicity, and ensuring reproducible large-scale manufacturing. Future directions focusing on improved targeting through ligand and receptor engineering, integration with advanced gene editing tools like CRISPR, and next-generation LNPs with enhanced functionalities are poised to expand the therapeutic potential and personalized applications of this versatile platform. Thus, lipid nanoparticles stand as a transformative technology with broad clinical prospects in infectious diseases, cancer, genetic disorders, and beyond, heralding a new era of precision medicine. The aim of this review is to comprehensively encapsulate the advancements, challenges, and clinical potential of lipid nanoparticles as drug delivery systems.